All In Biotech

Drug Trial Radar · NCT06441630

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

A Multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AD-227A and AD-227B Combination Treatment in Patients with Essential Hypertension

Last checked: Nov 19, 2026Latest source record: Feb 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 251 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

251

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Lead sponsor
Addpharma Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of co-administration of AD-227A and AD-227B in patients with essential hypertension

Conditions

  • Essential Hypertension

Interventions

  • AD-227ADrug

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • AD-227BDrug

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • AD-227CDrug

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • Placebo of AD-227BDrug

    Per Oral, 1 Tablet, Once a day for 8 weeks

  • Placebo of AD-227CDrug

    Per Oral, 1 Tablet, Once a day for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in MSSBPTime frame: Baseline to Week8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gangnam CHA Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.